| Q42378453 | 2L-PCA: a two-level principal component analyzer for quantitative drug design and its applications |
| Q36943923 | A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells |
| Q34556927 | Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy |
| Q35269067 | Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression |
| Q41703140 | Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopes |
| Q35152524 | An Aggressive Hypoxia Related Subpopulation of Melanoma Cells is TRP-2 Negative. |
| Q38284692 | Antigen-specific vaccines for cancer treatment |
| Q34557185 | Archaeosome adjuvant overcomes tolerance to tumor-associated melanoma antigens inducing protective CD8 T cell responses |
| Q36563301 | Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A*02:01 in vivo |
| Q34276512 | Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". |
| Q37390912 | B16 as a mouse model for human melanoma |
| Q36375693 | Coupling and uncoupling of tumor immunity and autoimmunity |
| Q36368308 | Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. |
| Q34677842 | Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine |
| Q38305306 | Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. |
| Q37139813 | Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling |
| Q28360452 | Evidence of the extrathymic development of tyrosinase-related protein-2-recognizing CD8+ T cells with low avidity |
| Q36310789 | Generation of murine tumor cell lines deficient in MHC molecule surface expression using the CRISPR/Cas9 system |
| Q36551911 | Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients |
| Q48772031 | Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas |
| Q36456716 | Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice |
| Q84152698 | Identification of tumor-associated antigens from medullary breast carcinoma by a modified SEREX approach |
| Q39057617 | Immune targets and neoantigens for cancer immunotherapy and precision medicine |
| Q36642248 | Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase |
| Q34792069 | Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells |
| Q37554202 | Inferring the Impact of Regulatory Mechanisms that Underpin CD8+ T Cell Control of B16 Tumor Growth In vivo Using Mechanistic Models and Simulation |
| Q36665434 | Interleukin-21 administration to aged mice rejuvenates their peripheral T-cell pool by triggering de novo thymopoiesis |
| Q40302175 | Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy |
| Q40077786 | Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity |
| Q37110386 | Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells |
| Q28344557 | Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy |
| Q42862258 | Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists |
| Q38622791 | Rehmannia glutinosa polysaccharide induces toll-like receptor 4 dependent spleen dendritic cell maturation and anti-cancer immunity. |
| Q35784865 | Replication-Competent Foamy Virus Vaccine Vectors as Novel Epitope Scaffolds for Immunotherapy |
| Q33770310 | Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries |
| Q33374550 | Side-chain conformational space analysis (SCSA): a multi conformation-based QSAR approach for modeling and prediction of protein-peptide binding affinities |
| Q40649080 | Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities |
| Q24338108 | Structural basis for the differential classification of HLA-A*6802 and HLA-A*6801 into the A2 and A3 supertypes |
| Q34509094 | Superior antitumor response induced by large stress protein chaperoned protein antigen compared with peptide antigen |
| Q43089933 | T-Cell Mediated Immune Responses Induced in ret Transgenic Mouse Model of Malignant Melanoma |
| Q37162647 | Targeted Programming of the Lymph Node Environment Causes Evolution of Local and Systemic Immunity |
| Q64107890 | The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review |
| Q35113904 | The TLR4 agonist fibronectin extra domain A is cryptic, exposed by elastase-2; use in a fibrin matrix cancer vaccine |
| Q52647650 | The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide. |
| Q33724224 | The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control |
| Q26863283 | Therapeutic cancer vaccines: past, present, and future |
| Q34484042 | Translating tumor antigens into cancer vaccines |
| Q37635491 | Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy |
| Q61797559 | Turning the corner on therapeutic cancer vaccines |
| Q41480929 | Unique peptide substrate binding properties of 110-kDa heat-shock protein (Hsp110) determine its distinct chaperone activity |
| Q33713083 | Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus |